DTX3L and prostate carcinoma: Accordingly, we demonstrate that DTX3L overexpression sensitizes prostate cancer cells to synthetic lethality by PARP inhibitors, highlighting that DTX3L overexpression indicates sensitivity to PARP inhibitors in cancers such as prostate cancer.